Novo Nordisk A/S-BNONOF
13F holders, Q3 2024 (September 30)2holders −1
0new positions
1sold out
$117.49avg. 13F price*
At the end of Q3 2024, 2 institutions reported holding Novo Nordisk A/S-B (NONOF) in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holders were Atlas Capital Advisors Inc. ($613K) and GAMMA Investing LLC ($30K).
- Company
- Novo Nordisk A/S-B
- CUSIP
- K72807140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $23.7M |
All 13F filers, Q2 2024 → Q3 2024: 164,577 shares sold, net −164,577 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Atlas Capital Advisors Inc. | 0.09% | No change | 5,218 | $613K |
| GAMMA Investing LLC | 0.00% | No change | 258 | $30K |
"% of holder's portfolio" is NONOF's weight in each manager's 13F, not the share of Novo Nordisk A/S-B the manager owns.